Publicaciones científicas
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Hermann Einsele 1 , Philippe Moreau 2 , Nizar Bahlis 3 , Manisha Bhutani 4 , Laure Vincent 5 , Lionel Karlin 6 , Aurore Perrot 7 , Hartmut Goldschmidt 8 , Niels W C J van de Donk 9 , Enrique M Ocio 10 , Joaquin Martinez-Lopez 11 , Paula Rodríguez-Otero 12 , Dominik Dytfeld 13 , Joris Diels 14 , Vadim Strulev 14 , Imene Haddad 15 , Thomas Renaud 16 , Eric Ammann 17 , Jedelyn Cabrieto 14 , Nolen Perualila 14 , Ryan Gan 18 , Youyi Zhang 16 , Trilok Parekh 19 , Claire Albrecht 15 , Katja Weisel 20 , Maria-Victoria Mateos 21
Introduction: Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results from the phase I/II MonumenTAL-1 trial. The relative effectiveness of talquetamab vs. real-world physician's choice of therapy (RWPC) was assessed using adjusted comparisons.
Methods: An external control arm for MonumenTAL-1 (subcutaneously administered talquetamab 0.4 mg/kg weekly [QW] and 0.8 mg/kg every other week [Q2W]) was created from two observational real-world studies: LocoMMotion and MoMMent. Imbalances in baseline covariates were adjusted using inverse probability weighting. The relative effectiveness of talquetamab vs. RWPC was estimated for overall response rate (ORR), ≥ very good partial response (VGPR), and ≥ complete response (CR); odds ratios and relative response ratios (RRs) were derived from weighted logistic regression. Hazard ratios (HRs) for duration of response (DOR), progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) were estimated using a weighted Cox proportional hazards model.
Results: After reweighting, baseline characteristics were balanced across cohorts. In adjusted comparisons, patients treated with talquetamab QW (n = 143) had significantly improved outcomes vs. RWPC; RRs were ORR 2.67, p < 0.0001; ≥ VGPR 4.70, p < 0.0001; ≥ CR 78.05, p = 0.0002; and HRs were PFS 0.52, p < 0.0001; TTNT 0.48, p < 0.0001; OS 0.36, p < 0.0001. Patients treated with talquetamab Q2W (n = 145) also had significantly improved outcomes vs. RWPC; RRs were ORR 2.62, p < 0.0001; ≥ VGPR 5.04, p < 0.0001; ≥ CR 101.14, p = 0.0002; and HRs were PFS 0.40, p < 0.0001; TTNT 0.39, p < 0.0001; OS 0.37, p < 0.0001.
Conclusion: Effectiveness of talquetamab for both schedules was significantly better than RWPC for ORR, ≥ VGPR, ≥ CR, PFS, OS, and TTNT, highlighting its clinical benefit for patients with TCE RRMM.
CITA DEL ARTÍCULO Adv Ther. 2024 Feb 24. doi: 10.1007/s12325-024-02797-x
Nuestros autores
